WHO strongly advises against antibody treatments for Covid-19 patients


Two antibody drugs that work by neutralising the SARS-CoV-2 virus' spike protein (foreground) are no longer recommended for treating Covid-19 due to their lack of effectiveness against current viral variants, including Omicron. — AFP/US NIH

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with Covid-19, said a World Health Organization (WHO) Guideline Development Group of international experts in The BMJ medical journal on Sept 16 (2022).

These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Health

Does taking vitamin C when you're sick really work?
Why rescue blankets have a silver and a gold side
'Engage your core!' – but how do you really do that?
Region-specific diets around China recommended to combat obesity
It’s tough becoming a dad – and they get little support too
A tired brain leads to bad decisions and bad behaviour
Diabetes: Empowering communities with peer support and social media
Lower your blood pressure by swapping just a few minutes of sitting for exercise
When uncontrolled diabetes causes you to go blind
New ways to combat the threat of antimicrobial resistance (AMR)

Others Also Read